Alto Ingredients, Inc.ALTONASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

zacks.com

4 Consumer Discretionary Stocks to Grab as Inflation Continues to Ease

ACEL, CROX, ALTO and DLB gain appeal as easing inflation boosts rate-cut hopes and earnings estimates climb for these consumer discretionary picks.

benzinga.com

Top 3 Materials Stocks That May Crash This Month

As of March 9, 2026, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

seekingalpha.com

Alto Ingredients: What's The Next Move, After A Long-Awaited Comeback?

Strong improvement in fiscal performance has sent Alto Ingredients up 180% over the past year. Continued capacity expansion is well-cited as a possible catalyst for shares, but another catalyst remains in motion for this industrial alcohol and renewable energy company. That would be Alto's potential to get acquired by a smaller competitor.

defenseworld.net

Reviewing Alto Ingredients (NASDAQ:ALTO) and Kid Brands (OTCMKTS:KIDBQ)

Kid Brands (OTCMKTS:KIDBQ - Get Free Report) and Alto Ingredients (NASDAQ: ALTO - Get Free Report) are both consumer discretionary companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk. Earnings and Valuation This table compares Kid

defenseworld.net

Critical Analysis: Alto Ingredients (NASDAQ:ALTO) & Reynolds Consumer Products (NASDAQ:REYN)

Reynolds Consumer Products (NASDAQ: REYN - Get Free Report) and Alto Ingredients (NASDAQ: ALTO - Get Free Report) are both consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Analyst Ratings This is a breakdown

benzinga.com

Alto Ingredients Stock Hits New 52-Week High: What's Driving The Rally?

Alto Ingredients Inc (NASDAQ: ALTO) shares are trading higher again Friday, extending a powerful two-day rally after the ethanol and specialty alcohol producer's blowout earnings report late Wednesday sparked a roughly 50% surge on Thursday. Here's what investors need to know.

zacks.com

Best Momentum Stock to Buy for March 6th

ALTO, SHG and ESCA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 6, 2026.

seekingalpha.com

Alto Ingredients: Buy On Strong Quarter And Multiple Tailwinds

Alto Ingredients reported strong fourth-quarter results with profitability well ahead of consensus expectations. Management attributed the outperformance to a combination of improved crush margins, high-margin export sales, lower operating expenses, and the recognition of clean fuel production tax credits. While Q1 will be impacted by seasonality and weather-related downtime, 2026 as a whole should benefit from strong export volumes and a doubling of tax credits.

benzinga.com

Why Alto Ingredients Stock Is Surging 50% Today

Alto Ingredients Inc (NASDAQ: ALTO) shares are surging Thursday afternoon as investors cheer a strong earnings report reinforcing the renewable fuels producer's turnaround. Here's what investors need to know.

seekingalpha.com

Alto Ingredients, Inc. (ALTO) Q4 2025 Earnings Call Transcript

globenewswire.com

Alto Ingredients, Inc. Reports Fourth Quarter and Year-end 2025 Results

- Results Improved in All Segments - - Q4 2025 Gross Profit of $15.2 Million Increased $16.6 Million, Q4 2025 Net Income of $21.5 Million, or $0.28 per Share, Improved $63.5 Million, and Q4 2025 Adjusted EBITDA of $27.9 Million Grew $35.6 Million Compared to Q4 2024 - PEKIN, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, reported its financial results for the quarter and year ended December 31, 2025.

defenseworld.net

Comparing Alto Ingredients (NASDAQ:ALTO) and Ceconomy (OTCMKTS:MTTRY)

Ceconomy (OTCMKTS:MTTRY - Get Free Report) and Alto Ingredients (NASDAQ: ALTO - Get Free Report) are both consumer discretionary companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation. Valuation and Earnings This table compares Ceconomy and

globenewswire.com

Alto Ingredients, Inc. to Release Fourth Quarter and Year-end 2025 Financial Results on March 4, 2026

PEKIN, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO) a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced it will release its fourth quarter and year-end 2025 financial results after the close of market on Wednesday, March 4, 2026.

defenseworld.net

Alto Ingredients (ALTO) to Release Quarterly Earnings on Wednesday

Alto Ingredients (NASDAQ: ALTO - Get Free Report) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Alto Ingredients to post earnings of $0.02 per share and revenue of $234.83 million for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page

defenseworld.net

Alto Ingredients (NASDAQ:ALTO) Trading Down 5.2% – What’s Next?

Alto Ingredients, Inc. (NASDAQ: ALTO - Get Free Report) dropped 5.2% during trading on Tuesday. The stock traded as low as $2.52 and last traded at $2.54. Approximately 556,388 shares changed hands during trading, a decline of 33% from the average daily volume of 824,512 shares. The stock had previously closed at $2.68. Wall Street

businesswire.com

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the.

seekingalpha.com

Alto Ingredients: The Market Is Pricing The Old Business, Not The New One

Alto Ingredients (ALTO) has transitioned from a pure ethanol producer to a diversified, higher-margin specialty ingredients and CO₂ business. Q3 results confirm a structural earnings inflection, with GAAP profitability, improved product mix, and cost discipline driving sustainable margin expansion. Section 45Z tax credits, effective 2026, will materially reset ALTO's earnings floor, providing multi-year regulatory cash flow visibility.